>Preliminary data in the research of cervical cancer, gastric cancer and other tumors show that Cadonilimab is significantly less toxic than the combination therapy of PD-1 and CTLA-4, and has obvious safety and efficacy advantages.
The new crown virus is really "upper" | 1/3 of patients still have neurological or mental illness 6 months later
Time of Update: 2021-04-24
The results showed that more than one-third Patients with new crowns were diagnosed with neurological or mental illnesses within six months of being infected with new crowns.
Orange peels and 5-hydroxy-6, 7, 8, 3', 4'-methoxyflavone are suppressed by activating the ROS-AKT/mTOR signaling path
Time of Update: 2021-01-12
Rheumatoid arthritis (RA) is a long-lasting and recurrent autoimmune disease. The School of Food Science and Engineering, Central South Forestry University, Rice and By-products Seed Processing National Engineering Laboratory
Hengrui Pharmaceutical CDK 4/6 Inhibitor Phase 3 clinical studies reached the main endpoint
Time of Update: 2021-01-05
Source: Pharmaceutical Mission Hills On December 24, Hengrui Pharmaceuticals announced that it had reached the end of a phase 3 clinical study in patients with advanced breast cancer in the study of CDK 4/6 inhibitor SHR6390 tablets. results
Research and development daily Henrui Pharmaceutical CDK 4/6 inhibitor Phase 3 clinical research reached the main...
Time of Update: 2021-01-05
diabetes. Drug Approval: Lilly CDK4/6 inhibitor Abemaciclib domestic listing in recent days, Lilly CDK4/6 inhibitor Abemaciclib tablets (i.e., Abesili tablets) of the listing application changed to "in-approval" in the NMPA status, which means
Lancet Neurology: 1, 2, 3 and 6 spinal cord microcephaly disorder risk individuals to explicit co-assistance disorder (RISCA): a longitudinal cohort study
Time of Update: 2020-11-06
Our goal is to study the sensitivity of obvious health mutation carriers associated with SCA1, SCA2, SCA3, and SCA6 to co-dysfunction and to detect changes in these individuals by clinical and functional indicators.
3 new anti-tumor drugs approved by Xinda Bio have been approved for clinical targets involving CTLA-4, GITR and PD-1.
Time of Update: 2020-10-19
Based on the Drug Clinical Trial Registration and Information Disclosure Platform, IBI310 has registered five clinical trials in China, including advanced hepatocellular carcinoma, melanoma, high microsatellite instability (MSI-H) or mismatch repair defect (dMMR) advanced colorectal cancer.
Taizhou Pharmaceutical High-tech Zone with the "4-3-1" characteristic industrial system, to create new advantages in development
Time of Update: 2020-06-16
Pharmaceutical Network Pharmaceutical Engineering Recently, the Jiangsu provincial government issued a circular to the province in 2019 to promote the relevant major policy measures to really work hard, to achieve significant results of the local
Hebei collection results publicity: nitrobenzene 1 minute 2 cents 3 metformin 4 minutes 3...
Time of Update: 2020-05-31
The price of generic drugs out of a new low a new round of national collection has not yet officially started, a number of generic drugs have once again refreshed the floor price - nitrobenzene (10mg) single piece 1 minute 2 minutes 3
Generics: "3-1" changes to "4-1", ADD ANOTHER MEMBER TO THE ED MARKET
Time of Update: 2020-05-31
At present, Jiangsu Tianslidi Yi Pharmaceutical Co., Ltd. Hedara non-opioid 4 generic drugs listing application in the State of NMPA is "certified completed - to be approved", but it is understood that the wholly-owned subsidiary Jiangsu Tianslidi Yi
New medical insurance era: PD-1 price has not yet bottomed out? How will the 4 + 3 competition
Time of Update: 2020-01-07
"Chinese companies are very vulnerable when it comes to health care negotiations, because there is no other market to take on the cost, so they've saved their lives." On January 5
Generic drugs: "3 + 1" becomes "4 + 1", and ED market adds another member
Time of Update: 2020-01-03
Original: dopine At present, the status of listing application of tadalafei tablet of Jiangsu tiansiliyi Pharmaceutical Co., Ltd
in nmpa is "certificate preparation
Hebei centralized mining results publicity: nifedipine 1 point 2 li 3 metformin 4 points 3
Time of Update: 2019-12-13
Does the generic medicine begin to be priced by "points"? A new round of national centralized purchase has not officially started, and several generic drugs have renewed their base
: synthesis of 3-trifluoromethyl-3-hydroxy-1-cyclohexanone by intermolecular [4 + 2] cyclization promoted by internal oxidants catalyzed by copper
Time of Update: 2019-07-15
Source: Professor Jiang Huanfeng's research group cyclohexanone is a kind of structural unit widely existing in many natural products, bioactive molecules and reaction
the first? 6 varieties are deemed to be passed, and 3 have won the bid of "4 + 7 centralized procurement"
Time of Update: 2019-01-16
On May 11, 2017, the State Food and Drug Administration issued a notice (No
54, 2017) on Soliciting Opinions on relevant policies on encouraging innovation
Drought in 1 / 4 soybean and 1 / 3 corn belt in China
Time of Update: 2001-06-04
At present, the drought areas in China include 1 / 4 soybean planting area and 1 / 3 corn planting area.